TERPS Trial for de Novo Oligometastic Prostate Cancer

Prostate Cancer Clinical Trial

Official title: Phase 2 Randomized Total Eradication of Metastatic Lesions Following Definitive Radiation to the Prostate in de Novo oligometaStatic Prostate Cancer (TERPS) Trial

Status Recruiting

Clinical Trial Summary

This research is being done to determine if we can improve the outcome of prostate cancer patients who have failed primary treatment - surgery or local radiation to the prostate - and have three or fewer bone or soft tissue metastases.

Clinical Trial Description

This study will compare the effects, good and/or bad, of using the standard of care treatment (systemic therapy + primary prostate radiation) compared to standard of care treatment plus stereotactic ablative radiation therapy (SABR) to metastatic lesions for prostate patients. The researchers are also trying to learn if the addition of SABR will affect recurrence rates. Presence of circulating tumor cells, gut bacteria, and quality of life will be assessed for both groups. ;

Related Conditions & MeSH terms

• Oligometastatic Disease
• Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT05223803
• Study type: Interventional
• Source: University of Maryland, Baltimore
• Contact: Phuoc Tran, MD
• Phone: 410-369-5200
• Email: Phuoc.Tran@umm.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: October 18, 2022
• Completion date: July 31, 2027